ReviewFrontiers in pharmacology2025
Protective effects of medicinal plant-derived metabolites in cardiovascular disease targeting exosomal pathways.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Traditional Chinese Medicine Formulas in Delaying Aging: From Theoretical Foundations to Molecular Mechanisms and Translational Perspectives.Journal of cellular and molecular medicine · 2026Review
- Ginsenoside Rg1 Ameliorates LPS-Induced Sepsis-Associated Lung Injury in Mice via VEGFC/D-VEGFR3 Signaling-Mediated Lymphangiogenesis and Lymphatic Remodeling.The Kaohsiung journal of medical sciences · 2026Article
- Mechanisms and emerging research trends of angiogenesis promotion by small extracellular vesicles from different cellular sources in alleviating myocardial infarction injury.Frontiers in pharmacology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease (CVD) is a highly prevalent and lethal disease worldwide, and existing conventional therapeutic drugs have limitations due to their side effects. Medicinal plant-derived metabolites have become a research hotspot due to their multi-target and multi-pathway cardioprotective potentials, while exosomal miRNAs, as core regulatory molecules of intercellular communication, play a key role in CVD such as atherosclerosis and myocardial infarction. This paper systematically reviews the mechanisms by which medicinal plant-derived metabolites regulate exosome miRNA or synergize with exosome therapy to protect CVD. For instance, Tanshinone IIA, Astragaloside IV, Paeonol, and Ginsenoside Rg1 can achieve effects such as promoting/inhibiting angiogenesis, anti-inflammation, and vascular remodeling by regulating exosomal miRNA expression. Finally, we look forward to the future direction of Medicinal plant-derived metabolites combined with exosomes in the protection of cardiovascular diseases, and provide a theoretical basis for the application of Medicinal plant-derived metabolites in CVD protection and the development of exosomal miRNA-targeted drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.